Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II

European Journal of Cancer Part A

Volumn 33, Issue 7, 1997, Pages 1141-1148

  Jungwirth, A ^a,c   Pinski, J ^a   Galvan, G ^a,c   Halmos, G ^a   Szepeshazi, K ^a   Cai, R Z ^a   Groot, K ^b   Vadillo Buenfil, M ^a   Schally, A V ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c St Johanns Spital   (Austria)

Author keywords

Androgen independent prostate cancer; Bombesin GRP antagonists; LH RH antagonist

Indexed keywords

BOMBESIN ANTAGONIST; CETRORELIX; GONADORELIN ANTAGONIST; RC 3940II; RC 3950II; TRIPTORELIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RELAPSE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; BOMBESIN; GASTRINS; GENITALIA, MALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; MALE; MICE; MICE, NUDE; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, BOMBESIN; RECEPTORS, LHRH; TESTOSTERONE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030814022     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00072-5     Document Type: Article

References (36)

1. Schroeder FH, Boyle P. Screening of prostate cancer-necessity or nonsense? Eur J Cancer 1993, 29A, 656-661.
2. Sharifi R, Soloway M. The Leuprolide Study Group. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol 1990, 143, 68-71.
3. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995, 76, 96-100.
4. Schally AV, Comaru-Schally AM, Gonzalez-Barcena D. Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer. Biomed Pharmacother 1990, 46, 465-471.
5. Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrin Metab 1995, 80, 2806-2814.
6. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line. Int J Cancer 1978, 21, 274-281.
7. Pinski J, Halmos G, Schally AV. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Lett 1993, 71, 189-196.
8. Connolly JM, Rose DP. Interaction between epidermal growth factor-mediated autocrine regulation and linoleic acid-stimulated growth of a human prostate cancer cell line. Prostate 1992, 20, 151-158.
9. Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res 1992, 52, 2538-2544.
10. Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Treat Res 1992, 21, 181-192.
11. Shirahige Y, Cook CB, Pinski J, Halmos G, Nair R, Schally AV. Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xeongrafts in nude mice. Int J Oncol 1994, 5, 1031-1035.
12. 4) bombesin by tumor cells. Prostate 1994, 25, 29-38.
13. Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer cells. Nature 1986, 316, 823-826.
14. Qin Y, Ertl T, Cai RZ, Halmos G, Schally AV. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res 1994, 54, 1035-1041.
15. Yano T, Pinski J, Groot K, Schally AV. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res 1992, 52, 4545-4547.
16. 2 showing high binding affinity to bombesin/GRP receptors in CFPAC-1 human pancreatic cancer cells. Int J Oncol 1995, 6, 1165-1172.
17. 2 or its derivatives. Proc Natl Acad Sci USA 1994, 91, 12664-12668.
18. Janik P, Briand P, Hartmann NR. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res 1975, 35, 3698-3704.
19. Pinski J, Schally AV, Halmos G, Szepeshazi K. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Int J Cancer 1993, 55, 963-967.
20. Halmos G, Pinski J, Szoke B, Schally AV. Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer. Cancer Lett 1994, 85, 111-119.
21. Szoke B, Horvath J, Halmos G, et al. LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro. Peptides 1994, 15, 359-366.
22. Munson JP, Rodbard D. A versatile computerized approach for characterization of ligand binding systems. Anal Biochem 1980, 107, 220-239.
23. Szepeshazi K, Cai RZ, Radulovic S, Milovanovic S, Szoke B, Schally AV. Inhibitory effect of bombesin/GRP antagonist RC-3095 and high dose of somatostatin analog RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res 1991, 51, 5980-5986.
24. Steel RGD, Torrie J. Principles and Procedures of Statistics. New York, McGraw Hill, 1976, 114.
25. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989, 63, 1714-1720.
26. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor α. Cancer Res 1991, 51, 2780-2785.
27. Angelloz-Nicoud P, Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 1995, 136, 5485-5492.
28. Yano T, Pinski J, Szepeshazi K, et al. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer 1994, 73, 1229-1238.
29. 11] substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small lung cancer cells in vitro. Proc Natl Acad Sci USA 1988, 81, 1859-1863.
30. Liebow C, Crean DH, Lee MT, Kramer AR, Mang TS, Schally AV. Synergistic effects of bombesin and epidermal growth factor on cancers may stimulate growth through upregulation of EGF receptors. Proc Natl Acad Sci USA 1994, 91, 3804-3808.
31. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on the human androgen-independent prostate cancer cell line DU-145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994, 54, 4091-4095.
32. Gonzales-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, et al. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia (BPH) and prostatic cancer. Prostate 1994, 24, 84-92.
33. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA 1994, 91, 7090-7094.
34. Redding TW, Schally AV. Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists. J Endocrinol 1990, 126, 309-315.
35. Pinski J, Yano T, Schally AV. Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats. Neuroendocrinology 1992, 56, 831-837.
36. Szepeshazi K, Halmos G, Groot K, Schally AV. Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist. Int J Pancreatol 1994, 16, 141-149.